These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 31167663

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
    Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW, CREDENCE Trial Investigators.
    N Engl J Med; 2019 Jun 13; 380(24):2295-2306. PubMed ID: 30990260
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
    Januzzi JL, Xu J, Li J, Shaw W, Oh R, Pfeifer M, Butler J, Sattar N, Mahaffey KW, Neal B, Hansen MK.
    J Am Coll Cardiol; 2020 Nov 03; 76(18):2076-2085. PubMed ID: 33121714
    [Abstract] [Full Text] [Related]

  • 28. Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial.
    Tanaka A, Imai T, Shimabukuro M, Nakamura I, Matsunaga K, Ozaki Y, Minamino T, Sata M, Node K, CANDLE trial investigators.
    J Diabetes Investig; 2022 Dec 03; 13(12):1990-1999. PubMed ID: 36114704
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study.
    Kario K, Hoshide S, Okawara Y, Tomitani N, Yamauchi K, Ohbayashi H, Itabashi N, Matsumoto Y, Kanegae H.
    J Clin Hypertens (Greenwich); 2018 Oct 03; 20(10):1527-1535. PubMed ID: 30246286
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.
    Vaduganathan M, Sattar N, Xu J, Butler J, Mahaffey KW, Neal B, Shaw W, Rosenthal N, Pfeifer M, Hansen MK, Januzzi JL.
    J Am Coll Cardiol; 2022 Feb 08; 79(5):432-444. PubMed ID: 35115099
    [Abstract] [Full Text] [Related]

  • 33. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
    Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P, CVD-REAL Investigators and Study Group*.
    Circulation; 2017 Jul 18; 136(3):249-259. PubMed ID: 28522450
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y.
    Adv Ther; 2019 Oct 18; 36(10):2567-2586. PubMed ID: 31444707
    [Abstract] [Full Text] [Related]

  • 36. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.
    Sen T, Li J, Neuen BL, Neal B, Arnott C, Parikh CR, Coca SG, Perkovic V, Mahaffey KW, Yavin Y, Rosenthal N, Hansen MK, Heerspink HJL.
    Diabetologia; 2021 Oct 18; 64(10):2147-2158. PubMed ID: 34415356
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: A systematic review and meta-analysis.
    Khan MS, Usman MS, Siddiqi TJ, Memon MM, Shah SJ, Khan SS.
    Eur J Prev Cardiol; 2019 Oct 18; 26(15):1680-1682. PubMed ID: 30755019
    [No Abstract] [Full Text] [Related]

  • 40. Can we go beyond surrogates?
    Drexler A.
    J Diabetes; 2017 Nov 18; 9(11):976-977. PubMed ID: 28692750
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.